<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482858</url>
  </required_header>
  <id_info>
    <org_study_id>AMCS-003</org_study_id>
    <nct_id>NCT01482858</nct_id>
  </id_info>
  <brief_title>Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorphical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amorphical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and analgesic effect (efficacy) of Gastrolith powder
      (GASP) on skeletal pain caused by osteoporotic vertebral compression fractures (OVCF) versus
      placebo, primarily as assessed by the Numeric Rating Scale (NRS), and Brief Pain Inventory
      (BPI). It is also intended to evaluate disability change with the Oswestry Low Back Pain
      Disability Index (ODI) and to evaluate whether GASP consumption leads to reduction in
      analgesic standard of care (ASOC) versus placebo, using weekly analgesic consumption diaries.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of pain assessed by change in NRS from baseline to end of the trial</measure>
    <time_frame>from baseline to end of the trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain assessed by change in BPI from baseline to end-of-trial</measure>
    <time_frame>baseline to end-of-trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of disability assessed by change in ODI from baseline to end-of-trial</measure>
    <time_frame>baseline to end-of-trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of ASOC assessed by weekly change in analgesic consumption diaries from baseline to end of trial</measure>
    <time_frame>baseline to end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All adverse events and serious adverse events will be collected and reported</measure>
    <time_frame>Baseline until four (4) weeks after completion of the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Gastrolith</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gastrolith</intervention_name>
    <description>Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.</description>
    <arm_group_label>Gastrolith</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoporotic patients aged 18-80 years old, inclusive.

          -  Diagnosed Osteoporotic vertebral compression fracture(s) in at least one vertebra
             caused by an atraumatic event or a minimal traumatic event such as falling from
             standing height or less, or by other minimal trauma besides a fall (see section 4.2
             Table I for definitions), and visible by either X-ray radiography, CT or MRI.

          -  At least six (6) weeks and no more than six (6) months from the onset of severe back
             pain suspected to be caused by the OVCF.

          -  Presenting a score of ≥5 in the pain NRS during movement (getting up from a chair).

          -  Subjects able to adhere to the visit schedule and protocol requirements and be
             available to complete the study.

          -  Subject that had signed the ICF.

        Exclusion Criteria:

          -  More than six (6) months from the onset of severe back pain suspected to be caused by
             OVCF.Subjects after vertebroplasty or kyphoplasty.

          -  Hypercalcemic subjects (calcium &gt; 10.50 mg/dL).

          -  Subjects with renal diseases.

          -  Subjects with active malignancy or other active metabolic bone disease which is not
             osteoporosis.

          -  Subjects with cognitive impairments.

          -  Pregnant or breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliad Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Ein Carem Medical Center, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galit Shaltiel-Glod, PhD</last_name>
    <phone>972 (0)8-6479411-</phone>
    <email>galits@amorphical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clalit Health Services - South District</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pesach Shwartzman, MD</last_name>
      <phone>972-(0)8-6477433</phone>
    </contact>
    <investigator>
      <last_name>Pesach Shwartzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pesach Shwartzman, MD</last_name>
      <phone>972-(0)8-6477433</phone>
    </contact>
    <investigator>
      <last_name>Pesach Shwartzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tsofia Ish-Shalom, MD</last_name>
      <phone>972-(0)4-8541533</phone>
    </contact>
    <investigator>
      <last_name>Tsofia Ish-Shalom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Carem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eliad Davidson, MD</last_name>
      <phone>972-(0)2-6776911</phone>
    </contact>
    <investigator>
      <last_name>Eliad Davidson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvio Brill, MD</last_name>
      <phone>972-(0)3-6974581</phone>
    </contact>
    <investigator>
      <last_name>Sylvio Brill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>November 30, 2011</last_update_submitted>
  <last_update_submitted_qc>November 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

